Pfizer Inc. (NYSE:PFE) closed at $28.40 on October 12. The stock has returned almost 4% during the last six months, compared to a 21.25% return for the Insider Monkey Billionaire Index and 14% for State Street SPDR S&P 500 ETF Trust.
Pfizer pays a 6% annual dividend yield that most income funds cannot ignore, and carries a reputation most of them would rather avoid. Whether that combination is generous or a warning is the only question worth asking here.
Pfizer Inc. ranked 6th on our list of the 14 Best Pharma Dividend Stocks to Buy in 2026. To see which stocks outranked it, click HERE.
One Weak Year Sets Both Numbers:
Trailing earnings are $0.77 a share against a forward estimate of $2.90, and almost everything odd about Pfizer’s screen follows from that single gap. A dividend costing more than double reported earnings is where the 226.32% payout comes from. That same $0.77 divided into a share price near twenty-eight dollars is where the 36.73 multiple comes from. Neither figure would look unusual against the forward estimate.
The cash tells a steadier story than the earnings. Free cash flow arrived at more than double reported net income, which is what makes a payout above two hundred percent of earnings actually payable.
The medicines themselves still earn well. Gross margin sits near three-quarters of revenue, and the operating margin is comfortably in the twenties, which is a normal shape for large pharmaceuticals rather than the profile of a broken business. Revenue also grew in the most recent quarter, so the top line is not what collapsed. That combination is what separates the real payers on the pharma dividends we rated highest this year from the ones that only look generous, and the drugmaker we put first there has returned 13% since.
A dividend is only as safe as the cash behind it, never the earnings in front of it. Pfizer passes that test on cash and fails it on reported profit, which is the whole of the argument above.
DON’T MISS: 14 Best Blue Chip Dividend Stocks to Buy According to Hedge Funds
The Patent Cliff Sits Behind the Yield:
Net margin of 6.80% against an operating margin in the high twenties is where the problem sits, and interest on $63.48 billion of debt lives inside that gap. That debt was largely raised to buy growth through acquisition, the same strategy its peers are running, because Pfizer has to replace revenue coming off patent. The forward multiple of 9.76 only applies if earnings per share really does reach $2.90 from $0.77, which is a very large recovery to assume and depends entirely on the acquired pipeline performing.
A yield above 6% is the market’s own verdict on that. Income investors do not get paid six percent by a large pharmaceutical company unless the market has doubts about the payout or the earnings behind it. The balance sheet is stretched rather than strained, with cash on hand and a current ratio above one, so this is a question of growth rather than solvency. Six percent is either a bargain or a warning, and an income buyer has to pick one, which is why many of them stay with the blue chip payers with the heaviest hedge fund ownership instead. The most crowded name there is up 23% since.
The Valuation Case:
The verdict is that Pfizer looks cheap on forward estimates and fairly valued on what it is actually earning today. Enterprise value against EBITDA of 15.72 is the least distorted measure available, and on that basis the shares are genuinely inexpensive relative to the sector.
You are buying a recovery that has not happened yet, paid for while you wait by a dividend covered by cash. Trading below twice book value gives some floor, more than most of the sector offers. What it does not give is the multi-decade record behind the dividend aristocrats with unbroken raise records.
Conclusion:
The two alarming figures are one weak trailing year counted twice. Free cash flow came in at more than double reported net income, and revenue is still growing. However, net margin carries the interest on an enormous debt load, and the forward multiple only holds if earnings per share recovers as sharply as analysts expect. A yield this high is what the market pays when it doubts that. Net margin is what the debt leaves behind, and it is the line to follow from here.
Market Sentiment:
Pfizer Inc. was held by 83 hedge funds with a combined stake value of about $4.71 billion at the end of Q2 2026 in the Insider Monkey database. This is level with 83 hedge fund holders with a cumulative investment value of around $6.15 billion in the previous quarter.
While we acknowledge the risk and potential of PFE as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PFE and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 14 Best Blue Chip Dividend Stocks to Buy According to Hedge Funds and 14 Best Pharma Dividend Stocks to Buy in 2026
This article is originally published at Insider Monkey.
